Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
This study is currently recruiting participants.
Verified November 2012
by Jiangsu HengRui Medicine Co., Ltd.
Study NCT01560195 Information provided by Jiangsu HengRui Medicine Co., Ltd.
First Received on March 8, 2012. Last Updated on November 4, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
Carcinoma, Non-Small-Cell Lung
More general conditions related to this trial
Body Temperature Changes
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Signs and Symptoms
Interventions listed in this trial
Pegylated rhG-CSF: 100µg/kg
Pegylated rhG-CSF: 6mg
placebo and rhG-CSF 5ug/kg/d
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Physiological Effects of Drugs
Sponsors listed in this trial
Jiangsu HengRui Medicine Co., Ltd.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers